Press release
Extended-Release Drugs Market Set to Reach $113.05 Billion by 2029 with 13% Yearly Growth
Extended-Release Drugs Market
The growth of the extended-release drug market is anticipated to be fueled by the rising prevalence of chronic diseases. These are defined as medical conditions lasting a year or more, necessitating continuous medical care and impeding daily activities. Examples encompass heart disease, cancer, obesity, and diabetes. Extended-release drug delivery systems aim to maintain a steady therapeutic effect by ensuring a nearly constant level of medication in the body over an extended period. This helps avoid fluctuations in drug levels that can follow the use of immediate-release medications. For example, the US-based National Library of Medicine, National Center for Biotechnology Information (NCBI), forecasted in January 2023 that the count of individuals 50 years and older with at least one chronic disease would increase by nearly 99.5%, reaching 142.66 million by 2050. Hence, the rising prevalence of chronic diseases is propelling the expansion of the extended-release drug market.
Get Your Extended-Release Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report
What growth opportunities are expected to drive the extended-release drugs market's CAGR through 2034?
The market size for extended-release medications has experienced swift expansion in the latest years. The growth is expected to continue, with the market value expected to rise from $63.11 billion in 2024 to $70.28 billion in 2025-an impressive compound annual growth rate (CAGR) of 11.4%. Factors such as advancements in patient compliance, the incidence of chronic diseases, increased effectiveness, strategic patent protection, and biodegradable implants have propelled the exceptional growth in the historical period.
In the upcoming years, the market size for extended-release drugs is set to experience a swift escalation. The market is anticipated to inflate to $113.05 billion by 2029, with a compound annual growth rate (CAGR) of 12.6%. The proliferation during the forecast period can be credited to factors such as the adoption of personalized medicine strategies, patient-oriented drug evolution, surge in lifestyle diseases, repurposing of drugs, and worldwide accessibility to extended-release treatments. Key trends paving the future include innovation within the pharmaceutical sector, progress in drug delivery systems, enhancement in nanotechnology, the application of 3D printing in drug concoctions, the implementation of artificial intelligence, and commitment to environmental sustainability.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp
How are the latest trends influencing the growth of the extended-release drugs market?
Pushing the boundaries in product innovation is becoming a significant trend in the extended-release drug market. Key players in the sector are introducing groundbreaking products to maintain their market prominence. For example, in July 2022, Zydus Pharmaceuticals (USA) Inc., a leading American generic pharmaceutical firm, rolled out Topiramate extended-release capsules for epilepsy. The company has received prior approval from The US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg. They are the first company in the US to secure final permission and launch Topiramate extended-release capsules. These capsules have been authorized in two ways for those who suffer from partial onset or primary generalized tonic-clinic seizure.
Which growth-oriented segments of the extended-release drugs market are leading the industry's development?
The extended-release drugs market covered in this report is segmented -
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12675
What regions are leading the charge in the extended-release drugs market?
North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What companies are at the forefront of innovation in the extended-release drugs market?
Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp
What Is Covered In The Extended-Release Drugs Global Market Report?
• Market Size Forecast: Examine the extended-release drugs market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the extended-release drugs market for a structured understanding.
• Key Players Overview: Analyze major players in the extended-release drugs market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the extended-release drugs market.
• Segment Contributions: Evaluate how different segments drive overall growth in the extended-release drugs market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the extended-release drugs market.
• Industry Challenges: Identify potential risks and obstacles affecting the extended-release drugs market.
• Competitive Landscape: Review strategic developments in the extended-release drugs market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Extended-Release Drugs Market Set to Reach $113.05 Billion by 2029 with 13% Yearly Growth here
News-ID: 3896331 • Views: …
More Releases from The Business Research Company
Global Gaucher's Disease Market: Major Drivers Reshaping the Future of the Indus …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Gaucher's Disease Industry Market Size Be by 2025?
The valuation of the Gaucher's disease sector has experienced consistent upward movement throughout the preceding years, projected to advance from its 2024 standing of $1.68 billion to reach $1.76 billion by 2025, reflecting a steady compound annual growth…
Rising Global Incidence Of Eye Illnesses Fuels Accelerated Growth In The Eyelid …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Eyelid Scrub Industry Market Size Be by 2025?
The market for eyelid scrubs has experienced substantial expansion lately, poised to increase from $3.7 billion in the year 2024 to $3.98 billion by 2025, reflecting a compound annual growth rate of 7.6%. This upward trajectory during the…
2025-2034 Esophageal Dysphagia Market Outlook: Key Drivers, Emerging Challenges, …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Esophageal Dysphagia Industry Market Size Be by 2025?
Recent years have seen significant expansion within the market concerning esophageal dysphagia, with projections indicating a rise from its 2024 valuation of $2.08 billion to $2.19 billion by 2025, reflecting a compound annual growth rate (CAGR) of 5.1%;…
Global Encephalitis Treatment Market Projected to Grow at 5.7% CAGR, Reaching $2 …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Encephalitis Treatment Industry Market Size Be by 2025?
The valuation of the encephalitis therapeutics sector has experienced a robust expansion lately, projecting an increase from its 2024 standing of $21.09 billion to $22.17 billion in 2025, reflecting a consistent compound annual growth rate of 5.1%; this…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
